Table 1. Relationship between miR-29b expression and their clinicopathological parameters in cervical cancer patients.
| Clinicolpathological parameters | Number of cases | Expression of miR-29b | P-value |
|---|---|---|---|
| Age (years): | |||
| < 40 | 15 | 2.678 ± 1.185 | 0.918 |
| ≥ 40 | 7 | 2.486 ± 0.768 | |
| Histology: | |||
| Squamous-cell carcinoma | 18 | 2.638 ± 1.003 | 0.958 |
| Adenocarcinoma | 4 | 2.520 ± 1.009 | |
| Tumor size before chemotherapy (cm): | |||
| < 4 | 16 | 3.095 ± 1.114 | 0.360 |
| ≥ 4 | 6 | 1.341 ± 0.528 | |
| Nodal status: | |||
| Positive | 20 | 2.268 ± 0.388 | 0.898 |
| Negative | 2 | 2.651 ± 0.917 | |
| Clinical stages: | |||
| Stage IB | 5 | 6.984 ± 3.003 | 0.002* |
| Stage IIA and IIB | 17 | 1.332 ± 0.243 | |
| HPV types: | |||
| HPV 16 | 19 | 2.594 ± 0.949 | 0.947 |
| Other types | 3 | 2.760 ± 1.386 |
Abbreviations: P-value represents the probability from a Student's t-test for miR-29b expression between variable subgroups. *P < 0.05 and **P < 0.01 were considered to have a significant difference.